Efficacy and tolerability of ®Estraderm MX, a new estradiol matrix patch

Maturitas

Volumn 27, Issue 3, 1997, Pages 285-292

  Bacchi Modena, Alberto ^a   Bolis, Pierfrancesco ^b   Campagnoli, Carlo ^c   De Cicco, Fiorenzo ^d   Meschia, Michele ^e   Pansini, Francesco ^f   Pisati, Roberto ^g   Hüls, Gabriele ^h  

^a UNIVERSITY OF PARMA   (Italy)

^b OSPEDALE DI CIRCOLO   (Italy)

^c Osp S Anna di Torino   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF FERRARA   (Italy)

^g Medical Department   (Italy)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Estradiol; Estrogen replacement therapy; Hot flushes; Menopausal symptoms; Placebo controlled trial; Transdermal

Indexed keywords

ESTRADIOL; ESTRONE SULFATE; PLACEBO; DRUG DERIVATIVE; ESTRONE;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HORMONAL REGULATION; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; BLOOD; CLIMACTERIUM; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTROGEN THERAPY; INTRADERMAL DRUG ADMINISTRATION; ITALY; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; CLIMACTERIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTRONE; FEMALE; HUMANS; ITALY; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0030611823     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(97)00039-X     Document Type: Article

References (19)

1. Sagraves R. Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis. J Clin Pharmacol 1995;35:2S-10S.
2. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992;117:1038-1041.
3. Ettinger B, Friedman GD, Bush T, Quesenberry CP. Reduced mortality associated with long-term post-menopausal estrogen therapy. Obstet Gynecol 1996;87:6-12.
4. Cheang A, Sitruk-Ware R, Utian WH. A risk-benefit appraisal of transdermal estradiol therapy. Drug Safety 1993;9:365-79.
5. Balfour JA, Heel RC. Transdermal Estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990;40:561-82.
6. Balfour JA, McTavish D. Transdermal Estradiol: A review of its pharmacological profile and therapeutic potential in the prevention of postmenopausal osteoporosis. Drugs and Aging 1992;2:487-507.
7. McBurney EI, Noel SB, Collins JH. Contact dermatitis to transdermal estradiol system. J Am Acad Dermatol 1989;20:508-19.
8. Schwartz BK, Clendenning WE. Allergic contact dermatitis from hydroxypropyl cellulose in transdermal estradiol patch. Contact Dermatitis 1988;18:106-7.
9. Torres V, Lopes JC, Leite L. Allergic contact dermatitis from nitroglycerin and estradiol transdermal therapeutic systems. Contact Dermatitis 1992;26:53.
10. Merz, PG, Keller-Stanislawsky B. Bioäquivalenz von zwei Estradiol-pflastern. In: Rietbrock N, Keller-Stanislawsky B, Woodcock BG, editors. Die Haut als Transportorgan für Arzneistoffe. Darmstadt: Steinkoppf-Verlag, 1990, 71-76.
11. McCarthy T, Dramusic V, Ratnam S. Use of two types of estradiol-releasing skin patches for menopausal subjects in a tropical climate. Am J Obstet Gynecol 1992;166:2005-10.
12. Howie H, Heimer G. A multicenter randomized parallel group study comparing a new estradiol matrix patch and a registered reservoir patch. J Nth Am Men Soc 1995;2:43-8.
13. Studd JWW, McCarthy K, Zamblera D, Burger HG, Silberberg S, Wren B, Dain MP, Le Lann L, Vandepol C. Efficacy and tolerability of Menorest® compared to Premarin® in the treatment of postmenopausal women. A randomized, Multicenter, double-blind, double-dummy study. Maturitas 1995;22:105-14.
14. Gordon SF. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy. Am J Obstet Gynecol 1995;173:998-1004.
15. Kupperman HS, Blatt MHG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab 1953;13:688-703.
16. Loriaux DL, Ruder HJ, Lipsett MB. The measurement of estrone sulfate in plasma. Steroids 1971;18:463-72.
17. Anderson ABM, Sklowsky E, Sayers L, Steele PA, Turnbull AC. Comparison of serum oestrogen concentrations in post-menopausal women taking oestrone sulphate and oestradiol. Brit Med J 1978;1:140-2.
18. Mueller P, Botta L, Ezzet F. Bioavailability of estradiol from a new matrix and a conventional reservoir type transdermal system (®Estraderm MX 50 and ®Estraderm TTS 50). Eur J Clin Pharmacol, 1996;51:327-330.
19. Selby LP, McGarrigle HHG, Peacock M. Comparison of the effects of oral and transdermal oestradiol administration on estrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women. Clin Endocrinol 1989;30:241-9.